Emcure expands injectables capacity, opens 3rd facility in Gujarat
时间:2024-09-29 04:04:44 阅读(143)
The third injectable facility of Emcure Pharmaceuticals in Mehsana, Gujarat, which was commissioned in August 2023, is now ready for commercial supplies to domestic and international markets. The company already has an oral formulations manufacturing line in Mehsana.
It also has a facility in Hinjawadi, Pune, with a capacity of 80.64 million vials per annum and another in Sanand, Gujarat, with a capacity to churn out 72 million vials per annum.
IPO-bound Emcure’s manufacturing operations cover oral solids, oral liquids and injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. The company’s subsidiary Gennova Biopharmaceuticals,also plans to use its mRNA platform, through which it launched the Covid-19 vaccine, forthree other vaccines for Zoster, Zika and Rabies.
Emcure’s injectable portfolio includes complex iron injectables, oncology, steroids, suspensions and emulsions. Emcure can produce high-potency injectables, particularly oncology products.
Emcure had filed a draft red herring prospectus (DRHP) on December 16 for its Rs 800 crore IPO. It is the 12th largest Indian pharmaceutical company and the largest pharmaceutical company in the gynaecology, blood-related and HIV antiviral therapeutics segment in the country.
For the international markets, the firm’s focus is on developing and commercialising products, which requires significant expertise and is subject to less competition and offers higher margins.
In Europe and other key target markets, they are focused on higher-value-added generics and complex injectables, such as Cidofovir and Meropenem. Europe is one of the focus areas in the hospital segment, as it is a large market for complex injectables products, such as Cidofovir, BiCNU and Treprostinil, the company’s DRHP said.
The company is working on `ready-to-use’ products that reduce multi-step dose preparation and enable ease of use by physicians.
猜你喜欢
- Sebi introduces ASBA-like facility for secondary market trading
- Radiant Cash Management IPO to open on Friday; sets price band at Rs 94-99 per share
- Sebi proposes measures to contain price volatility on shares in this segment
- Refund portal to be not accessible to PACL investors for 5 days due to technical issues- Sebi panel
- Recession fears set stocks on course for weekly drop
- Sebi allows foreign investors to trade in commodity derivatives
- Punjab CM Mann announces hike in sugarcane price to Rs 380 per quintal
- Ram Temple inauguration- Mamata slams PM Modi’s ‘gimmick show’, says Trinamool against dividing people on religious lines
- Sebi issues operational guidelines on ‘scheme of arrangement’ for entities with listed debt securities